TrivarX Ltd (ASX: TRI) - Share Price
- Current share price for TRI : $0.021
TrivarX Ltd (TRI), an ASX-listed company, is a mental health technology company pioneering the use of objective measures to aid in early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). The Company is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market.
TRI General Information +
| ASX Code | TRI |
| Website | http://www.trivarx.com |
| Industry/Sector | Health Care Technology |
| Market Cap ($M) | 24 |
| TRI Share Price | $0.021 |
| Day High | $0.021 |
| Day Low | $0.020 |
| Last Close | $0.021 |
| TRI Share Price Movement | - ( No change ) |
Prices as at 16:40, 29 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
TrivarX Ltd (TRI) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from TrivarX Ltd (TRI) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
TrivarX Ltd (TRI) price-sensitive announcements
TRI - CRO Engaged to Advance Stabl-Im Phase 1 Trial
TrivarX Limited has announced the engagement of Beyond Drug Development, a specialist Cont
TrivarX Ltd (TRI)
22 May 2026 | 9:36 AM
22 May 2026 | 9:36 AM
TRI - March 2026 Quarterly Activities Report and Appendix 4C
TrivarX Limited, an Australian healthcare technology company, reported significant progres
TrivarX Ltd (TRI)
30 Apr 2026 | 9:38 AM
30 Apr 2026 | 9:38 AM
TRI - Dr Danielle Meyrick appointed as CEO
On May 2, 2026, TrivarX Limited announced the appointment of Dr. Danielle Meyrick as the n
TrivarX Ltd (TRI)
29 Apr 2026 | 8:29 AM
29 Apr 2026 | 8:29 AM
TRI - Appendix 4D & Half-Year Financial Report to 31 December 2025
TrivarX Limited's Appendix 4D and half-year financial report for the period ending 31 Dece
TrivarX Ltd (TRI)
24 Feb 2026 | 2:53 PM
24 Feb 2026 | 2:53 PM
TrivarX Ltd (TRI) Recent ASX Announcements
TRI Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$0.94 | -$0.20 | -48.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.24 | -$0.40 | -63.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$1.80 | -$1.00 | -61.30% | 0.00 | 0.00 | 0.00% | 0.0% |
TRI Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| 4DMedical Limited (4DX) | $2,477M | 0.3304 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Pro Medicus Limited (PME) | $19,732M | 0.3919 | 0.2545 | 0.2962 | 171.5531 | 136.7507 | 105.5019 | 0.29% | 0.37% | 0.49% |
| TrivarX Ltd (TRI) | $24M | -0.4865 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
TRI Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 1.03 | 0.00 |
| Market | 0.29 | 13.30 | 1.15 | 0.67 |
| Sector | 0.67 | 22.30 | 1.60 | 2.48 |
TRI Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Anthony (Tony) Keating | Executive Director | 31 Jul 2024 |
| Mr Christopher Ntoumenopoulos | Non-Executive Director | 15 Feb 2023 |
| Mr David Edward Trimboli | Non-Executive Director, Non-Executive Chairman | 25 Aug 2022 |
TrivarX Ltd (TRI) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 19 Dec 2025 | NTOUMENOPOULOS, Christopher | Issued | Direct Shares | 6,250,000 | $0.008 | $50,000.000 |
| 19 Dec 2025 | TRIMBOLI, David | Issued | Indirect Shares | 6,250,000 | $0.008 | $50,000.000 |
| 19 Dec 2025 | NTOUMENOPOULOS, Christopher | Issued | Indirect Shares | 5,000,000 | $0.008 | $40,000.000 |
See all changes in directors' interest & trades for TrivarX Ltd (TRI) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
TRI Management
| Name | Position |
|---|---|
| Danielle Meyrick | Chief Executive Officer |
| Kai Sun | Chief Operating Officer |
| Nova Taylor | Joint Company Secretary |
| Cameron Jones | Joint Company Secretary |
TRI Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in TrivarX Ltd (TRI). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 42,502,362 (7.47%) | FIL Limited and the entities |
TRI Calendar of Events
| Date | Event |
|---|---|
| 23 February 2027 | Report (Interim) |
| 28 September 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
